14-day Premium Trial Subscription Sign Up For FreeGet Free

CytomX Therapeutics Stock Forecast NASDAQ:CTMX

Price Target and Analyst Ratings

Most Recent Rating

On August 09, 2021 "HC Wainwright" gave "$12.00" rating for CTMX. The price target was changed from $5.23 to 0.4%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-09 $12.00 Reiterated by HC Wainwright $5.19 $5.23→0.4%
2021-07-06 $12.00 Reiterated by HC Wainwright $6.08 $6.07+1.2%
2021-07-06 Buy Reiterated by HC Wainwright $6.08 $12.00
2021-05-28 Equal Weight - Underweight Downgraded by Barclays $7.16 $9.00 → $7.00
2021-03-29 Overweight Initiated by JPMorgan Chase & Co. $7.59 $14.00
2021-03-29 Hold - Buy Upgraded by Jefferies Financial Group $7.59
2021-03-23 Hold - Buy Upgraded by Jefferies Financial Group $8.76
2020-11-08 Hold Reiterated by Barclays $7.02 $9.00
2020-09-22 Buy - Neutral Downgraded by Guggenheim $6.72
2020-09-15 Target Lowered by Citigroup $7.22 $11.00 → $8.50
2020-08-07 Buy Reiterated by HC Wainwright $7.62 $12.00
2020-06-01 Buy - Hold Downgraded by Jefferies Financial Group $8.06 $16.00 → $10.00
2020-05-29 Buy Reiterated by Mizuho $8.86 $16.00
2020-05-17 Buy Reiterated by Nomura $9.01 $15.00
2020-05-14 Buy Target Lowered by HC Wainwright $9.23 $16.00 → $12.00
2020-05-10 Buy Reiterated by Nomura $14.24 $15.00
2020-05-08 Buy Target Raised by HC Wainwright $14.24 $14.00 → $16.00

CTMX Stock Trend

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $5.23 will firstly indicate a slower falling rate, but may be the first sign of a trend shift.

Given the current short-term trend, the stock is expected to fall -27.49% during the next 3 months and, with a 90% probability hold a price between $2.70 and $3.79 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-20 $3.69 $4.44 $5.20
2021-09-21 $3.66 $4.41 $5.17
2021-09-22 $3.63 $4.38 $5.13
2021-09-23 $3.60 $4.35 $5.10
2021-09-24 $3.56 $4.32 $5.07
2021-09-27 $3.53 $4.29 $5.04
2021-09-28 $3.50 $4.26 $5.01
2021-09-29 $3.47 $4.22 $4.98
2021-09-30 $3.44 $4.19 $4.95
2021-10-01 $3.41 $4.16 $4.91
2021-10-04 $3.38 $4.13 $4.88
2021-10-05 $3.34 $4.10 $4.85
2021-10-06 $3.31 $4.07 $4.82
2021-10-07 $3.28 $4.04 $4.79
2021-10-08 $3.25 $4.00 $4.76
2021-10-11 $3.22 $3.97 $4.73
2021-10-12 $3.19 $3.94 $4.69
2021-10-13 $3.16 $3.91 $4.66
2021-10-14 $3.12 $3.88 $4.63
2021-10-15 $3.09 $3.85 $4.60
2021-10-18 $3.06 $3.81 $4.57
2021-10-19 $3.03 $3.78 $4.54
2021-10-20 $3.00 $3.75 $4.51
2021-10-21 $2.97 $3.72 $4.47
2021-10-22 $2.94 $3.69 $4.44
2021-10-25 $2.90 $3.66 $4.41
2021-10-26 $2.87 $3.63 $4.38
2021-10-27 $2.84 $3.59 $4.35
2021-10-28 $2.81 $3.56 $4.32
2021-10-29 $2.78 $3.53 $4.29

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition, it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., ImmunoGen, Inc., and Th... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT